If you are uninsured, have a prescription for, and need to get started immediately with one of these Gilead medications, click on the appropriate link below.

1. Gilead Co-pay Card
2. Gilead Copay Card Truvada

Support Path is a program that can help patients get started on Gilead and Asegua treatments. Call now to connect live with a Support Path Program Navigator at 1-855-7-MYPATH (1-855-769-7284). The Gilead CoPay card will basically pay your copay - no monthly limits but with a $7,200 yearly limit. You may be able to receive TRUVADA for PrEP free of charge if you qualify for the Medication Assistance Program. During these unprecedented times, Gilead is focused on being a resource and supporting the efforts of healthcare providers, colleagues, and partners who are on the front lines of the COVID-19 fight. Gilead continues to be dedicated to ensuring people living with HIV have access to the HIV medications and support needed.

BIKTARVY® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg) tablets

TRUVADA® (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) tablets

DESCOVY® (emtricitabine 200 mg/tenofovir alafenamide 25 mg) tablets

GENVOYA® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg) tablets

ODEFSEY® (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg) tablets

If you qualify for free medication, you can print your pharmacy medication card immediately and take your card, along with your prescription, to the pharmacy of your choice. Please note that Advancing Access will follow up with your prescriber for their signature on the Advancing Access enrollment form. If your prescriber's signature is not received within 30 days, your medication card will be deactivated and you will no longer receive free medication.

If you are with your healthcare professional, please have them go to the Advancing Access HCP portal to enroll you for access to free product with a pharmacy medication card.

If you are NOT with your healthcare professional, please go to the Advancing Access Patient Assist Portal.

INDICATION

BIKTARVY^® is indicated as a complete regimen for the treatment of HIV-1 infection in adult and pediatric patients weighing ≥25 kg who have no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA <50 copies per mL) on a stable ARV regimen with no history of treatment failure and no known resistance to any component of BIKTARVY.

Please see below for Important Safety Information for BIKTARVY.

Insurance Information Support

• Benefits investigations
• Prior authorization information
• Alternative coverage options

Financial Support

• Co-pay support*
• Assistance in finding alternative funding
• Uninsured 24/7 support

Eligible patients may pay as little as a

$0 co-pay*

with no monthly limit

Gilead Co-pay Card

Eligible patients may pay as little as a

$0 co-pay*

with no monthly limit

*For eligible commercially insured patients only. Restrictions apply. See full terms and conditions at gileadadvancingaccess.com/hcp/financial-assistance/copay-support

Two options for getting patients started:

Call 1-800-226-2056

Monday-Friday | 9 AM to 8 PM ET

Find your next unforgettable stay at one of the distinct hotels in the Curio Collection by Hilton. Curiosity rover. Curio Cabinets 'When it comes to your most valued possessions, many people feel uneasy about displaying them on a coffee table or end table where people may knock them over if the table gets bumped. Eliminate some of that worry with a lighted curio cabinet. Curio definition is - something (such as a decorative object) considered novel, rare, or bizarre: curiosity; also: an unusual or bizarre person. How to use curio in a sentence. Thymes and DPM Fragrance, the parent company of Capri Blue and Aspen Bay Candles, have merged to create CURiO ™, a powerful new platform in the prestige bath, body and home fragrance market. Curio cabinets are built to display more than your favorite dinnerware—think collectibles and mementos. Typically, curios feature glass panels on the front as well as along the sides to give a full view of the objects you want to display. Take your pick of gorgeous furniture finishes from light to medium to dark wood and mirrored options.

†Sourced from Decision Resources Group. Data are current as of September 2019. Individual plans may vary.

INDICATION

BIKTARVY^® is indicated as a complete regimen for the treatment of HIV-1 infection in adult and pediatric patients weighing ≥25 kg who have no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA <50 copies per mL) on a stable ARV regimen with no history of treatment failure and no known resistance to any component of BIKTARVY.

IMPORTANT SAFETY INFORMATION

BOXED WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B

• Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of BIKTARVY. Closely monitor hepatic function with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue BIKTARVY. If appropriate, anti-hepatitis B therapy may be warranted.

Contraindications

• Coadministration: Do not use BIKTARVY with dofetilide or rifampin.

Warnings and precautions

• Drug interactions: See Contraindications and Drug Interactions sections. Consider the potential for drug interactions prior to and during BIKTARVY therapy and monitor for adverse reactions.
• Immune reconstitution syndrome, including the occurrence of autoimmune disorders with variable time to onset, has been reported.
• New onset or worsening renal impairment: Cases of acute renal failure and Fanconi syndrome have been reported with the use of tenofovir prodrugs. In clinical trials of BIKTARVY, there have been no cases of Fanconi syndrome or proximal renal tubulopathy (PRT). Do not initiate BIKTARVY in patients with estimated creatinine clearance (CrCl) <30 mL/min. Patients with impaired renal function and/or taking nephrotoxic agents (including NSAIDs) are at increased risk of renal-related adverse reactions. Discontinue BIKTARVY in patients who develop clinically significant decreases in renal function or evidence of Fanconi syndrome.
  Renal monitoring: Prior to or when initiating BIKTARVY and during therapy, assess serum creatinine, CrCl, urine glucose, and urine protein in all patients as clinically appropriate. In patients with chronic kidney disease, assess serum phosphorus.

Please see below for additional Important Safety Information for BIKTARVY.

IMPORTANT SAFETY INFORMATION (cont'd)

Warnings and precautions (cont'd)

• Lactic acidosis and severe hepatomegaly with steatosis: Fatal cases have been reported with the use of nucleoside analogs, including FTC and TDF. Discontinue BIKTARVY if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity develop, including hepatomegaly and steatosis in the absence of marked transaminase elevations.

Adverse reactions

• Most common adverse reactions (incidence ≥5%; all grades) in clinical studies through week 144 were diarrhea (6%), nausea (6%), and headache (5%).

Drug interactions

• Prescribing information: Consult the full prescribing information for BIKTARVY for more information on Contraindications, Warnings, and potentially significant drug interactions, including clinical comments.
• Enzymes/transporters: Drugs that induce P-gp or induce both CYP3A and UGT1A1 can substantially decrease the concentration of components of BIKTARVY. Drugs that inhibit P-gp, BCRP, or inhibit both CYP3A and UGT1A1 may significantly increase the concentrations of components of BIKTARVY. BIKTARVY can increase the concentration of drugs that are substrates of OCT2 or MATE1.
• Drugs affecting renal function: Coadministration of BIKTARVY with drugs that reduce renal function or compete for active tubular secretion may increase concentrations of FTC and tenofovir and the risk of adverse reactions.

Dosage and administration

• Dosage: Patients weighing ≥25 kg: 1 tablet taken once daily with or without food.
• Renal impairment: Not recommended in patients with CrCl <30 mL/min.
• Hepatic impairment: Not recommended in patients with severe hepatic impairment.
• Prior to or when initiating: Test patients for HBV infection.
• Prior to or when initiating, and during treatment: As clinically appropriate, assess serum creatinine, CrCl, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, assess serum phosphorus.

Pregnancy and lactation

• Pregnancy: There is insufficient human data on the use of BIKTARVY during pregnancy. Dolutegravir, another integrase inhibitor, has been associated with neural tube defects. Discuss the benefit-risk of using BIKTARVY during pregnancy and conception. An Antiretroviral Pregnancy Registry (APR) has been established. Available data from the APR for FTC shows no difference in the rates of birth defects compared with a US reference population.
• Lactation: Women infected with HIV-1 should be instructed not to breastfeed, due to the potential for HIV-1 transmission.

Please see full Prescribing Information for BIKTARVY^® and DESCOVY^®, including BOXED WARNINGS.

Reference: 1. Data on file. Gilead Sciences, Inc.

During these unprecedented times, Gilead is focused on being a resource and supporting the efforts of healthcare providers, colleagues, and partners who are on the front lines of the COVID-19 fight. Gilead continues to be dedicated to ensuring people living with HIV have access to the HIV medications and support needed.

We are also working to ensure continuity of supply and continued access to our existing medicines. There are no manufacturing concerns or supply shortages with any Gilead products. We have adequate supply of our products and do not foresee any threat to our supply chain for the foreseeable future.

Gilead Copay Card Truvada

For the latest information, visit the links below: